Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
http://linked.open...drugbank/halfLife
| - 28 hours (range 10-50 hours) (en)
|
http://linked.open...ugbank/indication
| - For the treatment and management of leprosy and dermatitis herpetiformis. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| |
http://linked.open.../drugbank/synonym
| - DADPS (en)
- DDS (en)
- Dapsonum (en)
- P,P-Sulphonylbisbenzamine (en)
- P,P-Sulphonylbisbenzenamine (en)
- DAPSONE (en)
- 1,1'-Sulfonylbis(4-aminobenzene) (en)
- 1,1'-Sulfonylbis[4-aminobenzene] (en)
- 4,4'-Dapsone (en)
- 4,4'-Diaminodiphenyl sulfone (en)
- 4,4'-Diaminodiphenyl sulphone (en)
- 4,4'-Diaminodiphenylsulfone (en)
- 4,4'-Sulfonylbisaniline (en)
- 4,4'-Sulfonylbisbenzenamine (en)
- 4,4'-Sulfonylbisbenzeneamine (en)
- 4,4'-Sulfonyldianilin (en)
- 4,4'-sulfonyldianiline (en)
- 4-(4-Aminophenylsulfonyl)aniline (en)
- 4-(4-Aminophenylsulfonyl)benzenamine (en)
- 4-(4-amino-Benzenesulfonyl)-phenylamine (en)
- 4-Aminophenyl sulfone (en)
- Bis(4-aminophenyl)sulfone (en)
- Bis(P-aminophenyl) sulfone (en)
- DIAPHENYLSULFONE (en)
- Dapsona (en)
- P,P'-diaminodiphenyl sulfone (en)
- P-Aminophenyl sulfone (en)
|
http://linked.open...drugbank/toxicity
| - Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take without regard to meals. (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - Weijiard, J.and Messerly, J.P.; U.S. Patent 2,385,899; October 2,1945; assigned to Merck & Co., Inc. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...logy/drugbank/pKa
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Bioavailability is 70 to 80% following oral administration. (en)
|
http://linked.open.../affectedOrganism
| |